Intergenomic signatures of coevolution between Tasmanian devils and an infectious cancer

Proc Natl Acad Sci U S A. 2024 Mar 19;121(12):e2307780121. doi: 10.1073/pnas.2307780121. Epub 2024 Mar 11.

Abstract

Coevolution is common and frequently governs host-pathogen interaction outcomes. Phenotypes underlying these interactions often manifest as the combined products of the genomes of interacting species, yet traditional quantitative trait mapping approaches ignore these intergenomic interactions. Devil facial tumor disease (DFTD), an infectious cancer afflicting Tasmanian devils (Sarcophilus harrisii), has decimated devil populations due to universal host susceptibility and a fatality rate approaching 100%. Here, we used a recently developed joint genome-wide association study (i.e., co-GWAS) approach, 15 y of mark-recapture data, and 960 genomes to identify intergenomic signatures of coevolution between devils and DFTD. Using a traditional GWA approach, we found that both devil and DFTD genomes explained a substantial proportion of variance in how quickly susceptible devils became infected, although genomic architectures differed across devils and DFTD; the devil genome had fewer loci of large effect whereas the DFTD genome had a more polygenic architecture. Using a co-GWA approach, devil-DFTD intergenomic interactions explained ~3× more variation in how quickly susceptible devils became infected than either genome alone, and the top genotype-by-genotype interactions were significantly enriched for cancer genes and signatures of selection. A devil regulatory mutation was associated with differential expression of a candidate cancer gene and showed putative allele matching effects with two DFTD coding sequence variants. Our results highlight the need to account for intergenomic interactions when investigating host-pathogen (co)evolution and emphasize the importance of such interactions when considering devil management strategies.

Keywords: co-GWAS; coevolution; genomics; host–pathogen; joint phenotype.

MeSH terms

  • Animals
  • Communicable Diseases*
  • Daunorubicin / analogs & derivatives*
  • Facial Neoplasms* / genetics
  • Facial Neoplasms* / veterinary
  • Genome-Wide Association Study
  • Marsupialia* / genetics

Substances

  • 7-O-(2,6-dideoxy-2-fluorotalopyranosyl)daunomycinone
  • Daunorubicin

Supplementary concepts

  • Sarcophilus harrisii